Panorama NIPT

9+ weeks

Panorama® is a safe and simple way for expectant mothers to gain certain information about the health of their fetus without an invasive diagnostic procedure. Panorama uses a simple blood draw from the mother to examine cell-free DNA found in maternal blood originating from both mother and fetus to screen for chromosome abnormalities, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), monosomy X (Turner syndrome), and triploidy. The screening test can be performed as early as nine weeks of gestation and there is no risk to the fetus.

Natera® is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. 

Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer.

natera-logo
panorama-logo

Click here to visit: Panorama test for Patients

TEST NATERA
Company website http://global.panoramatest.com/uk
COMPANY Natera
Test Origin USA
Laboratory Location USA (Currently)
Type of cfDNA analysis SNP-Based Next-Generation Sequencing
Screen Population General, Low and High risk
Number of tests performed >475,000 (as of December 2015)
Clinical data number re test performance >20,000
About the test
Gestational age 9+ weeks
Pregnancies Screened
Singletons
Naturally conceived YES
IVF (Self) YES
IVF (Donor) No
Multiples (Twins)
Naturally conceived No
IVF (Self) No
IVF (Donor) No
Risk analysis All give individualized risk score plus high / low result for each patient
Fetal fraction redraw level 2.8% Minimum
Fetal fraction quoted Yes
Redraw rate 4% (~3% average for UK)
Chance of result after 2nd blood sample 68%
Chromosomes analysis Current validated detection rates (08/14)
Combined false positive rate T12/T18/T13 <0.1%
T21 Down’s syndrome >99%
T18 Edwards’ syndrome >96.4%
T13 Patau’s syndrome >99%
Triploidy YES
Fetal sex / presence of Y chromosome: accuracy YES: 100%
Sex Aneuploid Conditions YES
X0 (Turner syndrome) YES
XXX (Triple X) YES
XYY (Jacob’s syndrome) YES
XXY (Klinefelter syndrome) YES
Micro deletions (Optional) YES: 22q, Cri-du-Chat, 1p36, Angelman, Prader-Willi
Turnaround Time (TAT) working days UK average: 4 business days from receipt of sample